Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Presented Phase 2 Clinical Data for Etrasimod in Ulcerative Colitis at the American College of Gastroenterology Annual Meeting
SAN DIEGO , Oct. 8, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from its OASIS Phase 2 clinical study for its investigational drug candidate etrasimod, a next-generation, oral, S1P receptor modulator with optimized activity being evaluated in
View HTML
Toggle Summary Arena Pharmaceuticals Reports Positive Long-Term Data from the Ongoing Open-Label Extension of the Phase 2 Trial Evaluating Ralinepag for Treatment of Pulmonary Arterial Hypertension
- Ralinepag demonstrated durable, long-term improvements in both PVR and 6MWD - Favorable long-term tolerability profile demonstrated SAN DIEGO , Oct. 2, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive data from a planned interim analysis of the ongoing
View HTML
Toggle Summary Arena Pharmaceuticals Reports Positive Phase 2a Results for Olorinab in Patients with Abdominal Pain Associated with Crohn's Disease
- Olorinab demonstrated a statistically significant improvement in abdominal pain over 8 weeks of treatment - All patients with evaluable data at week 8 exhibited a pre-defined clinical response of ≥30% change from baseline in AAPS - Treatment effects were demonstrated early and were consistent
View HTML
Toggle Summary Arena Pharmaceuticals to Host R&D Day on October 4 in New York City
SAN DIEGO , Sept. 21, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will host an R&D Day to outline key catalysts and new information on the clinical programs for its potentially first- or best-in-class late-stage investigational compounds:
View HTML
Toggle Summary Arena Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO , Sept. 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in the upcoming investor conferences: Cantor Global Healthcare Conference – Presenting on Tuesday, October 2 , at 1:40 p.m.
View HTML
Toggle Summary Arena Pharmaceuticals Presents Preclinical Data for Olorinab at International Association for the Study of Pain World Congress
SAN DIEGO , Sept. 17, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that results from preclinical studies of its investigative drug candidate olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor 2 (CB 2 ) in development
View HTML
Toggle Summary Arena Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO , Aug. 29, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in the upcoming investor conferences: Wells Fargo Securities Global Healthcare Conference – Presenting on Wednesday, September 5 at 2:25
View HTML
Toggle Summary Arena Pharmaceuticals Presented Phase 1 Clinical Data for Ralinepag in Pulmonary Arterial Hypertension at the European Society of Cardiology
SAN DIEGO , Aug. 28, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from two Phase 1 clinical studies evaluating an extended-release (XR) formulation of its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2018 Financial Results
- Initiated ADVANCE Phase 3 Program for Ralinepag in Pulmonary Arterial Hypertension (PAH) - Completed Enrollment for Olorinab Study for Pain Associated with Crohn's Disease; Data in Q3:18 - Submitted Etrasimod Meeting Request to the FDA for Ulcerative Colitis (UC) SAN DIEGO , Aug.
View HTML
Toggle Summary Arena Pharmaceuticals to Release Second Quarter 2018 Financial Results and Provide Corporate Update on Monday, August 6
SAN DIEGO , July 30, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will release its second quarter 2018 financial results and provide a corporate update on Monday, August 6, 2018 , after the close of the U.S.
View HTML